Lido Advisors LLC Sells 12,664 Shares of Zoetis Inc. $ZTS

Lido Advisors LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 42.4% during the 1st quarter, Holdings Channel reports. The firm owned 17,207 shares of the company’s stock after selling 12,664 shares during the period. Lido Advisors LLC’s holdings in Zoetis were worth $2,035,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the fourth quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the first quarter worth $28,000. Lodestone Wealth Management LLC bought a new stake in Zoetis during the fourth quarter worth $30,000. Root Financial Partners LLC lifted its stake in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in Zoetis in the fourth quarter valued at $32,000. Institutional investors own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Morgan Stanley reduced their price target on Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $119.50.

Insider Activity

In other news, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Zoetis Stock Performance

NYSE ZTS opened at $75.32 on Monday. The firm has a 50-day moving average of $77.29 and a 200-day moving average of $104.08. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a market cap of $31.58 billion, a PE ratio of 12.49, a P/E/G ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is presently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.